News brief
On 2026/6/30, Xiniu Data reported that Purui Life Sciences completed CNY 100 million in Series A funding, led by Dongrong Fund One (Zhuhai Hengqin) Equity Investment Partnership (Limited Partnership), with participation from Sumitomo Corporation Asia Capital, Suzhou Rongsheng Xianxing Venture Investment Partnership (Limited Partnership), Suzhou High-Tech Science and Technology Innovation Angel Phase One Venture Investment Partnership (Limited Partnership), Qiming Venture Partners, IQVIA, and others. The company provides digital and intelligent clinical research services.
Connected profiles
Explore
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
2026年6月30日，据烯牛数据报道，璞睿生命科技完成A轮融资，金额1亿人民币。投资方为东融壹号（珠海横琴）股权投资合伙企业（有限合伙）领投，住友商事亚洲资本、苏州融晟先行创业投资合伙企业（有限合伙）、苏州高新科创天使一期创业投资合伙企业（有限合伙）、启明创投、IQVIA等跟投。该公司为数智化临床研究服务商。